Compare Ecolab Inc. (ECL) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Ecolab Inc. trades at $288.87 (market cap $80.08B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Ecolab Inc. is far larger — about 82.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Ecolab Inc. pays a 1.02% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 91 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ECL | MRVI | |
|---|---|---|
Market Cap | $80.08B | $972.90M |
Volume | 1,150,296 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $9.00 |
52-Week Low | $245.73 | $2.83 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $88.86B | $1.08B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $287.79, up 1.23% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 12.57% net income margin and 21.85% ROE, with revenue growth from $16.08B in 2025 to a projected $16.8B in 2026. Recent news highlights its dividend consistency and High-Tech segment growth, while institutional buying and insider purchases reflect confidence.
Outlook is positive with a consensus price target of $326.38, implying 13% upside, driven by earnings beats and digital expansion. Risks include elevated P/E of 38.34 and rising debt from the CoolIT acquisition. The stock remains a buy for growth-oriented investors, balancing steady cash flows with execution risks in a competitive market.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
